Dr. Reddy S Laboratories

DRREDDY NSE Healthcare Pharmaceuticals
Nifty 50 Nifty 100 Nifty 200 Nifty 500 LargeMid 250 F&O
₹1,165.50
+1.97%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.2.
  • Comfortable interest cover: operating profit covers interest about 17.3 times.
  • Return on equity is moderate at 11.2%.
  • Return on capital employed is moderate at 13%.
  • Net profit margin is 12.3%.
  • Profit has compounded about 15% a year over five years.
  • Sales have compounded about 12% a year over five years.
  • Pays a dividend (yield about 0.7%).
  • Has paid a dividend in each of the last 5 years on record.

!Watch-points

  • Recent profit growth (-43%) is slower than the five-year pace (15%).
  • Promoter holding is relatively low (26.63%).

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreGrey zone
2.93

This middle range was less conclusive in Altman’s study — neither clearly safe nor clearly distressed.

Computed without the working-capital term (current-asset split not available for this stock).

Piotroski F-ScoreWeak
3 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap₹ 97,085 Cr
Current Price₹ 1,165.50
High / Low₹ 1,414.90 / 1,101.00
Stock P/E29.298643
Book Value₹ 454.00
Dividend Yield0.7%
ROCE13.00%
ROE11.20%
Face Value₹ 1.00
Debt to Equity0.20
PEG Ratio
EV / EBITDA12.19
Industry PE35.25
P/B Ratio2.5320113
EPS₹ 50.27
Debt₹ 7,734 Cr
PAT Margin12.34%
Cash PAT₹ 6,217 Cr
ICR17.26
Promoter Holding26.63%
FII Holding20.67%
DII Holding31.75%
Public Holding20.76%

Note on calculated ratios: where a value is not published in the source data, we compute it from the reported financials — Debt to Equity = total borrowings ÷ (equity capital + reserves); EV / EBITDA = (market cap + debt − cash) ÷ (operating profit + depreciation); PEG = P/E ÷ 3-year profit growth %. These may differ slightly from other sources that use different periods or TTM figures. Current Price, Market Cap and P/E reflect the live quote (cached 15 min).

Compounded Sales Growth
10 Years 8.00%
5 Years 12.00%
3 Years 11.00%
TTM -1.00%
Compounded Profit Growth
10 Years 7.00%
5 Years 15.00%
3 Years -4.00%
TTM -43.00%
Stock Price CAGR
10 Years 6.00%
5 Years 3.00%
3 Years 1.00%
1 Year -9.00%
Return on Equity
10 Years 15.00%
5 Years 16.00%
3 Years 16.00%
Last Year 11.00%
Educational data only. Not a recommendation to buy, sell or hold any security.